CN100478026C - 用于生物学组分的传递系统 - Google Patents
用于生物学组分的传递系统 Download PDFInfo
- Publication number
- CN100478026C CN100478026C CNB028236785A CN02823678A CN100478026C CN 100478026 C CN100478026 C CN 100478026C CN B028236785 A CNB028236785 A CN B028236785A CN 02823678 A CN02823678 A CN 02823678A CN 100478026 C CN100478026 C CN 100478026C
- Authority
- CN
- China
- Prior art keywords
- weight
- transmission system
- premix
- pectin
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000894006 Bacteria Species 0.000 claims abstract description 20
- 239000006041 probiotic Substances 0.000 claims abstract description 6
- 230000000529 probiotic effect Effects 0.000 claims abstract description 6
- 235000018291 probiotics Nutrition 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims description 71
- 239000003792 electrolyte Substances 0.000 claims description 57
- 230000005540 biological transmission Effects 0.000 claims description 51
- 230000008859 change Effects 0.000 claims description 44
- 241000186660 Lactobacillus Species 0.000 claims description 38
- 229940039696 lactobacillus Drugs 0.000 claims description 38
- 235000010987 pectin Nutrition 0.000 claims description 38
- 229920001277 pectin Polymers 0.000 claims description 38
- 239000001814 pectin Substances 0.000 claims description 38
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 35
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 35
- 235000021355 Stearic acid Nutrition 0.000 claims description 34
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 34
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 34
- 239000008117 stearic acid Substances 0.000 claims description 34
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 33
- 229910052710 silicon Inorganic materials 0.000 claims description 33
- 239000010703 silicon Substances 0.000 claims description 33
- 239000004575 stone Substances 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 31
- 210000002784 stomach Anatomy 0.000 claims description 28
- 229920001282 polysaccharide Polymers 0.000 claims description 19
- 239000005017 polysaccharide Substances 0.000 claims description 19
- 235000010417 guar gum Nutrition 0.000 claims description 13
- 239000000665 guar gum Substances 0.000 claims description 13
- 229960002154 guar gum Drugs 0.000 claims description 13
- 229920002907 Guar gum Polymers 0.000 claims description 12
- 229920000926 Galactomannan Polymers 0.000 claims description 6
- -1 hydroxypropyl Chemical group 0.000 claims description 6
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 43
- 238000013270 controlled release Methods 0.000 abstract description 34
- 238000000034 method Methods 0.000 abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 description 43
- 230000009286 beneficial effect Effects 0.000 description 40
- 239000002552 dosage form Substances 0.000 description 36
- 238000009472 formulation Methods 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 30
- 230000009969 flowable effect Effects 0.000 description 28
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 27
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 27
- 239000011159 matrix material Substances 0.000 description 27
- 239000000945 filler Substances 0.000 description 22
- 244000005700 microbiome Species 0.000 description 22
- 229920000642 polymer Polymers 0.000 description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 20
- 238000004108 freeze drying Methods 0.000 description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 20
- 239000008108 microcrystalline cellulose Substances 0.000 description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 description 20
- 230000035479 physiological effects, processes and functions Effects 0.000 description 19
- 150000004804 polysaccharides Chemical class 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 16
- 238000000576 coating method Methods 0.000 description 16
- 239000002775 capsule Substances 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 15
- 230000002496 gastric effect Effects 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 229920002472 Starch Polymers 0.000 description 14
- 239000002274 desiccant Substances 0.000 description 14
- 229940032147 starch Drugs 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 239000000758 substrate Substances 0.000 description 13
- 239000000428 dust Substances 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 12
- 229920001206 natural gum Polymers 0.000 description 12
- 239000001993 wax Substances 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 229920000159 gelatin Polymers 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 108010010803 Gelatin Proteins 0.000 description 9
- 230000003628 erosive effect Effects 0.000 description 9
- 239000008273 gelatin Substances 0.000 description 9
- 235000011852 gelatine desserts Nutrition 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 229920001477 hydrophilic polymer Polymers 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000036571 hydration Effects 0.000 description 7
- 238000006703 hydration reaction Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000003124 biologic agent Substances 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 239000012738 dissolution medium Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000007907 direct compression Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229920000591 gum Polymers 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229920001285 xanthan gum Polymers 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007692 rcm medium Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920000161 Locust bean gum Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000004203 carnauba wax Substances 0.000 description 3
- 230000009920 chelation Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007515 enzymatic degradation Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 235000010420 locust bean gum Nutrition 0.000 description 3
- 239000000711 locust bean gum Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 230000010148 water-pollination Effects 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000692822 Bacteroidales Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- OUHCZCFQVONTOC-UHFFFAOYSA-N [3-acetyloxy-2,2-bis(acetyloxymethyl)propyl] acetate Chemical compound CC(=O)OCC(COC(C)=O)(COC(C)=O)COC(C)=O OUHCZCFQVONTOC-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical group Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010433 feldspar Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 101150107144 hemC gene Proteins 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005511 kinetic theory Methods 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Abstract
Description
剂量方案(mg) | A1(CTRL) | A2 | A3 | A4 | A5 |
乳酸菌预混合物 | 150 | 150 | 150 | 150 | 150 |
HPMC | 0 | 0 | 0 | 200 | 0 |
PEO | 0 | 0 | 0 | 0 | 200 |
MCC | 0 | 200 | 0 | 0 | 0 |
麦芽糖糊精 | 0 | 0 | 200 | 0 | 0 |
硬脂酸 | 16 | 16 | 16 | 16 | 16 |
硅石 | 16 | 16 | 16 | 16 | 16 |
总重量 | 182 | 382 | 382 | 382 | 382 |
剂量方案(mg) | B1(ctrl) | B2 | B3 | B4 |
乳酸菌预混合物 | 150 | 150 | 150 | 150 |
HPMC | 00 | 100 | 100 | 100 |
NaHCO<sub>3</sub> | 0 | 100 | 0 | 0 |
NaHCO<sub>3</sub> | 0 | 0 | 100 | 0 |
NaH<sub>2</sub>PO<sub>4</sub> | 0 | 0 | 0 | 100 |
硬脂酸 | 16 | 16 | 16 | 16 |
硅石 | 16 | 16 | 16 | 16 |
总重量 | 182 | 382 | 382 | 382 |
剂量方案(mg) | C1(ctrl) | C2 | C3 |
乳酸菌预混合物 | 150 | 150 | 150 |
HPMC | 0 | 100 | 100 |
果胶 | 0 | 100 | 0 |
明胶 | 0 | 0 | 100 |
硬脂酸 | 16 | 16 | 16 |
硅石 | 16 | 16 | 16 |
总重量 | 182 | 382 | 382 |
剂量方案(mg) | C1(ctrl) | C4 |
乳酸菌预混合物 | 150 | 150 |
果胶 | 0 | 200 |
硬脂酸 | 16 | 16 |
硅石 | 16 | 16 |
总重量 | 182 | 382 |
剂量方案(mg) | D1(ctrl) | D2 |
乳酸菌预混合物 | 150 | 150 |
瓜尔胶 | 0 | 100 |
NaHCO<sub>3</sub> | 0 | 100 |
果胶 | 0 | 100 |
硬脂酸 | 16 | 16 |
硅石 | 16 | 16 |
总重量 | 182 | 482 |
剂量方案(mg) | E1 | E2 |
乳酸菌预混合物 | 150 | 150 |
HPMC | 50 | 50 |
NaHCO<sub>3</sub> | 50 | 50 |
MCC | 200 | 200 |
果胶 | 50 | 50 |
硬脂酸 | 16 | 16 |
硅石 | 16 | 16 |
姜黄 | 2 | 2 |
总重量 | 443 | 443 |
剂量方案(mg) | F2 | F3 |
双岐杆菌属细菌预混合物 | 150 | 150 |
HPMC | 150 | 0 |
PEO | 0 | 150 |
果胶 | 100 | 100 |
NaHCO<sub>3</sub> | 100 | 100 |
硬脂酸 | 16 | 16 |
硅石 | 16 | 16 |
总重量 | 532 | 532 |
剂量方案(mg) | G1(CTRL) | G2 |
乳酸菌预混合物 | 150 | 150 |
果胶 | 0 | 75 |
HPMC | 0 | 110 |
NaHCO<sub>3</sub> | 0 | 110 |
瓜尔胶 | 0 | 200 |
硬脂酸 | 10 | 10 |
硅石 | 10 | 10 |
总重量 | 170 | 665 |
剂量方案(mg) | H1 | H2 |
乳酸菌预混合物 | 75 | 150 |
HPMC | 50 | 100 |
果胶 | 50 | 100 |
NaHCO<sub>3</sub> | 50 | 100 |
MCC | 100 | 200 |
硬脂酸 | 8 | 16 |
硅石 | 8 | 16 |
姜黄 | 1 | 2 |
总重量 | 342 | 684 |
剂量方案(mg) | I1 | I2 |
乳酸菌预混合物 | 150 | 150 |
HPMC | 100 | 100 |
果胶 | 100 | 100 |
NaH(CO<sub>3</sub>)<sub>2</sub> | 100 | 100 |
MCC | 200 | 200 |
硬脂酸 | 8 | 8 |
硅石 | 8 | 8 |
姜黄 | 2 | 2 |
总重量 | 684 | 684 |
剂量方案(mg) | H1 | H1 |
乳酸菌预混合物 | 75 | 75 |
HPMC,4000mPa | 50 | 0 |
HPMC,15000mPa | 0 | 50 |
果胶 | 50 | 50 |
NaHCO<sub>3</sub> | 50 | 50 |
MCC | 100 | 100 |
硬脂酸 | 8 | 8 |
硅石 | 8 | 8 |
姜黄 | 1 | 1 |
总重量 | 342 | 342 |
剂量方案(mg) | K1 |
乳酸菌预混合物 | 75 |
HPMC | 50 |
果胶 | 50 |
NaHCO<sub>3</sub> | 50 |
MCC | 100 |
硬脂酸 | 8 |
硅石 | 8 |
姜黄 | 2 |
总重量 | 343 |
Claims (12)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32593701P | 2001-09-28 | 2001-09-28 | |
US60/325,937 | 2001-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1596124A CN1596124A (zh) | 2005-03-16 |
CN100478026C true CN100478026C (zh) | 2009-04-15 |
Family
ID=23270074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028236785A Expired - Lifetime CN100478026C (zh) | 2001-09-28 | 2002-09-30 | 用于生物学组分的传递系统 |
Country Status (13)
Country | Link |
---|---|
US (2) | US8007777B2 (zh) |
EP (1) | EP1429802B1 (zh) |
JP (1) | JP5041651B2 (zh) |
KR (1) | KR100979877B1 (zh) |
CN (1) | CN100478026C (zh) |
AU (1) | AU2002330187B2 (zh) |
CA (2) | CA2461708C (zh) |
DK (1) | DK1429802T3 (zh) |
ES (1) | ES2398910T3 (zh) |
HK (1) | HK1066969A1 (zh) |
PT (1) | PT1429802E (zh) |
RU (1) | RU2313355C2 (zh) |
WO (1) | WO2003026687A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106535909A (zh) * | 2014-07-01 | 2017-03-22 | 普罗比美国公司 | 双层双重释放益生菌片剂 |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070098784A1 (en) * | 2001-09-28 | 2007-05-03 | Nutraceutix, Inc. | Delivery system for biological component |
ITMI20022344A1 (it) * | 2002-11-05 | 2004-05-06 | Biofarm Srl | Prodotto in pellicola a rapida dissoluzione in acqua, per il trattamento del latte con batteri e/o enzimi. |
US8871266B2 (en) * | 2003-10-01 | 2014-10-28 | Commonwealth Scientific & Industrial Research Organisation | Probiotic storage and delivery |
AU2004275438B2 (en) * | 2003-10-01 | 2008-05-29 | Commonwealth Scientific & Industrial Research Organisation | Probiotic storage and delivery |
WO2005060937A1 (en) * | 2003-12-23 | 2005-07-07 | Chr. Hansen A/S | Compressed tablets comprising viable probiotic microorganisms |
GB0330009D0 (en) | 2003-12-24 | 2004-01-28 | Ferrosan As | Probiotic tablet formulations |
JP2007524690A (ja) * | 2004-02-17 | 2007-08-30 | ヴェーリ・インター・アーゲー | 活性物質の生体内利用効率を高めるためのガラクトマンナン及び/又はグルコマンナン |
JP2007530683A (ja) * | 2004-03-31 | 2007-11-01 | ビーピーエスアイ ホールディングス,インコーポレーテッド | 経口摂取可能な基材の腸溶性コーティング |
EP1871868A2 (en) * | 2005-04-15 | 2008-01-02 | North Carolina State University | Methods and compositions to modulate adhesion and stress tolerance in bacteria |
US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
JP5100634B2 (ja) * | 2006-03-24 | 2012-12-19 | 興和株式会社 | 口腔内速崩壊性錠剤 |
WO2008002058A1 (en) * | 2006-06-26 | 2008-01-03 | B.M.Tech World Co., Ltd. | Method of preparing powder kimchi and kimchi composition using the same |
ITMI20062286A1 (it) * | 2006-11-28 | 2008-05-29 | Anidral Srl | Una composizione per la somministrazione di principi biologicamente attivi in ambito ginecologico e rettale nonche' i suoi usi |
ITMI20070452A1 (it) * | 2007-03-07 | 2008-09-08 | Anidral Srl | Compressa comprendente microrganismi ed una combinazione di eccipienti e relativo procedimento di produzione |
US8035401B2 (en) | 2007-04-18 | 2011-10-11 | Cypress Semiconductor Corporation | Self-calibrating driver for charging a capacitive load to a desired voltage |
US9720805B1 (en) | 2007-04-25 | 2017-08-01 | Cypress Semiconductor Corporation | System and method for controlling a target device |
TW200904340A (en) | 2007-05-11 | 2009-02-01 | Mannatech Inc | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same |
US9186640B2 (en) * | 2007-08-28 | 2015-11-17 | Pepsico, Inc. | Delivery and controlled release of encapsulated lipophilic nutrients |
US20100272859A1 (en) * | 2007-08-28 | 2010-10-28 | Pepsico, Inc. | Delivery and controlled release of encapsulated water-insoluble flavorants |
US20100055180A1 (en) * | 2007-10-10 | 2010-03-04 | Mallinckrodt Baker, Inc. | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
BRPI0818317A8 (pt) * | 2007-10-10 | 2018-12-18 | Mallinckrodt Baker Inc | composição, métodos de fabricação de excipiente, comprimido farmacêutico e método de fabricação do mesmo |
TW200927141A (en) * | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
EP2163239A1 (de) * | 2008-05-27 | 2010-03-17 | Qiagen GmbH | Produkte, die Biopartikel enthalten, Verfahren zu ihrer Herstellung |
ES2553852T3 (es) * | 2008-08-04 | 2015-12-14 | Dsm Ip Assets B.V. | Producción de perlas que comprenden compuestos probióticos |
ES2642620T3 (es) * | 2008-08-28 | 2017-11-17 | Chr. Hansen A/S | Composición bacteriana |
FR2938405B1 (fr) * | 2008-11-20 | 2011-04-22 | Florane | Complement alimentaire et procede de distribution d'un tel complement |
BRPI1009121A2 (pt) | 2009-03-04 | 2018-06-19 | Orexo Ab | formulações resistentes a abuso |
KR101830080B1 (ko) | 2009-05-08 | 2018-02-21 | 엠플리큐어 아베 | 지오폴리머성 결합제를 포함하는 지속형 약물 전달 조성물 |
US20110123677A1 (en) * | 2009-11-25 | 2011-05-26 | Pepsico, Inc. | High acid beverage products and methods to extend probiotic stability |
DK2613784T3 (da) | 2010-09-07 | 2018-01-29 | Emplicure Ab | Indretning til transdermal indgivelse af lægemiddel |
JP2013537221A (ja) * | 2010-09-17 | 2013-09-30 | ラヴリー・プロフェッショナル・ユニヴァーシティ | 改良された経口標的化薬物送達システム |
EP2627770B1 (en) | 2010-10-15 | 2017-06-28 | Cornell University | Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders |
US9667240B2 (en) | 2011-12-02 | 2017-05-30 | Cypress Semiconductor Corporation | Systems and methods for starting up analog circuits |
ITMI20131578A1 (it) * | 2013-09-25 | 2015-03-26 | Giellepi S P A | Sostanza e formulazione per il trattamento delle malattie infiammatorie croniche intestinali |
CA2941694A1 (en) | 2014-03-06 | 2015-09-11 | Research Institute At Nationwide Children's Hospital | Probiotic formulations and methods for use |
US10624934B2 (en) | 2014-03-06 | 2020-04-21 | Research Institute At Nationwide Children's Hospital | Prebiotic formulations |
FR3018193B1 (fr) * | 2014-03-10 | 2017-09-08 | Probionov | Comprime vaginal muco-adhesif a liberation prolongee |
US20170028183A1 (en) * | 2014-04-08 | 2017-02-02 | Mayo Foundation For Medical Education And Research | Ingestible capsule |
TWI829098B (zh) * | 2015-01-02 | 2024-01-11 | 美商梅拉洛伊卡公司 | 細菌組成物 |
TWI759260B (zh) | 2015-01-02 | 2022-04-01 | 美商梅拉洛伊卡公司 | 多元補充品組成物 |
WO2016109853A2 (en) | 2015-01-02 | 2016-07-07 | Melaleuca, Inc. | Dietary supplement compositions |
JP7283216B2 (ja) * | 2018-05-17 | 2023-05-30 | 大正製薬株式会社 | 経口組成物 |
AU2018428571A1 (en) | 2018-06-18 | 2021-01-28 | Probi Ab | Lactobacillus plantarum compositions and uses thereof |
CA3103326A1 (en) | 2018-06-18 | 2019-12-26 | Probi Ab | Probiotic compositions and uses thereof |
GB201905386D0 (en) | 2019-04-16 | 2019-05-29 | Probi Ab | Probiotic compositions and uses thereof |
GB201908154D0 (en) | 2019-06-07 | 2019-07-24 | Probi Ab | Lactobacillus compositions and uses thereof |
GB201908706D0 (en) | 2019-06-18 | 2019-07-31 | Probi Ab | Lactobacillus compositions and uses thereof |
EP3937983A4 (en) | 2019-12-17 | 2022-12-14 | 9286-3620 Québec Inc. | ORAL DELIVERY SYSTEMS BASED ON THE IN SITU FORMATION OF PROTEIN/POLYSACCHARIDE COACERVATES |
JP6944036B1 (ja) * | 2020-11-05 | 2021-10-06 | 株式会社ファンケル | ハードカプセル製剤 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB825480A (en) * | 1957-07-13 | 1959-12-16 | Johann Carl Pflueger | Improvements in or relating to ingestible dry micro-organism preparations and method for producing the same |
US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
US4542020A (en) | 1984-08-17 | 1985-09-17 | E. R. Squibb & Sons, Inc. | Long-lasting adhesive antifungal suppositories |
EP0205336B1 (en) | 1985-06-11 | 1991-09-11 | Teijin Limited | Oral sustained release pharmaceutical preparation |
US4755180A (en) | 1986-06-16 | 1988-07-05 | Alza Corporation | Dosage form comprising solubility regulating member |
US4806368A (en) * | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
IE60311B1 (en) | 1987-09-24 | 1994-06-29 | American Home Prod | Sustained release etodolac |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
US5194172A (en) | 1990-09-13 | 1993-03-16 | The Procter & Gamble Company | Aerated and freezer bar soap compositions containing sucrose as a mildness aid and a processing aid |
ZA927277B (en) * | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
US5288507A (en) * | 1992-07-29 | 1994-02-22 | Merck & Co., Inc. | Ibuprofen antacid combinations |
US5419917A (en) | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
US5531681A (en) * | 1995-01-13 | 1996-07-02 | Abbott Laboratories | Apparatus for altering composition of nutritional product during enteral tube feeding |
US5830884A (en) * | 1995-01-18 | 1998-11-03 | National Starch And Chemical Investment Holding Corporation | Pharmaceutical products containing thermally-inhibited starches |
JP2859216B2 (ja) * | 1995-08-10 | 1999-02-17 | 日清製粉株式会社 | 耐酸性に優れた腸内有用細菌含有顆粒の製造方法 |
US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
EP0813866A3 (en) * | 1996-06-17 | 1999-01-20 | Eisai Co., Ltd. | Therapeutic agent for joint diseases |
US5830503A (en) | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
AU6464698A (en) | 1997-03-21 | 1998-10-20 | Kimberly-Clark Worldwide, Inc. | Dual-zoned absorbent webs |
IL123984A (en) | 1997-04-22 | 2004-09-27 | Akzo Nobel Nv | Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable |
MY129120A (en) | 1997-08-19 | 2007-03-30 | Global Palm Products Sdn Bhd | Process for the production of monoglyceride based on the glycerolysis of methyl ester |
KR100387245B1 (ko) * | 1997-10-17 | 2003-08-19 | 일양약품주식회사 | 유산균의안정화를위한미세장용성코팅과립 |
US6337091B1 (en) | 1997-10-27 | 2002-01-08 | Temple University - Of The Commonwealth System Of Higher Education | Matrix for controlled delivery of highly soluble pharmaceutical agents |
US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
SE9801287D0 (sv) * | 1998-04-14 | 1998-04-14 | Astra Ab | Incorporation of active substances in carrier matrixes |
KR20000011247A (ko) * | 1998-07-23 | 2000-02-25 | 김윤 | 다당류를이용한대장선택성약물전달조성물및약학제제 |
US7498310B1 (en) | 1998-08-13 | 2009-03-03 | Beiersdorf Ag | Cosmetic or dermatological preparations comprising oligopeptides for lightening the skin of age marks and/or for preventing tanning of the skin, in particular tanning of the skin caused by UV radiation |
JP2003522731A (ja) * | 1998-12-11 | 2003-07-29 | ウレックス バイオテック インク. | 泌尿生殖器感染に対する処置および防止のための乳酸菌の経口投与方法 |
EP1072258A1 (de) * | 1999-07-28 | 2001-01-31 | Greither, Peter | Eine Kapsel für die Freisetzung von Bakterien, enthaltend ein Bakterienlyophilisat und ein Verfahren zu ihrer Herstellung |
US6375994B1 (en) | 1999-08-20 | 2002-04-23 | Sun Ten Laboratories, Inc. | Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability |
US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
WO2003024427A1 (en) | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US6458384B2 (en) * | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
US6777000B2 (en) * | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
NL1018100C2 (nl) | 2001-05-18 | 2002-11-19 | Stork Titan Bv | Inrichtingen voor het bereiden van stroombaar beslag en doseereenheid. |
US20030021841A1 (en) | 2001-07-02 | 2003-01-30 | Matharu Amol Singh | Pharmaceutical composition |
US7122370B2 (en) | 2003-01-14 | 2006-10-17 | Randolph Stanley Porubcan | Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life |
-
2002
- 2002-09-30 KR KR1020047004649A patent/KR100979877B1/ko active IP Right Grant
- 2002-09-30 DK DK02766451.5T patent/DK1429802T3/da active
- 2002-09-30 PT PT2766451T patent/PT1429802E/pt unknown
- 2002-09-30 RU RU2004110617/15A patent/RU2313355C2/ru active
- 2002-09-30 EP EP02766451A patent/EP1429802B1/en not_active Expired - Lifetime
- 2002-09-30 CA CA2461708A patent/CA2461708C/en not_active Expired - Lifetime
- 2002-09-30 AU AU2002330187A patent/AU2002330187B2/en not_active Ceased
- 2002-09-30 US US10/261,639 patent/US8007777B2/en not_active Expired - Fee Related
- 2002-09-30 CN CNB028236785A patent/CN100478026C/zh not_active Expired - Lifetime
- 2002-09-30 ES ES02766451T patent/ES2398910T3/es not_active Expired - Lifetime
- 2002-09-30 WO PCT/US2002/031309 patent/WO2003026687A1/en active Application Filing
- 2002-09-30 CA CA2778208A patent/CA2778208C/en not_active Expired - Lifetime
- 2002-09-30 JP JP2003530322A patent/JP5041651B2/ja not_active Expired - Fee Related
-
2004
- 2004-12-13 US US11/010,607 patent/US20050152966A1/en not_active Abandoned
- 2004-12-22 HK HK04110177.0A patent/HK1066969A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106535909A (zh) * | 2014-07-01 | 2017-03-22 | 普罗比美国公司 | 双层双重释放益生菌片剂 |
Also Published As
Publication number | Publication date |
---|---|
PT1429802E (pt) | 2013-01-24 |
JP2005528324A (ja) | 2005-09-22 |
EP1429802B1 (en) | 2012-11-07 |
AU2002330187B2 (en) | 2008-01-03 |
ES2398910T3 (es) | 2013-03-22 |
RU2313355C2 (ru) | 2007-12-27 |
KR20040045027A (ko) | 2004-05-31 |
EP1429802A1 (en) | 2004-06-23 |
JP5041651B2 (ja) | 2012-10-03 |
CA2778208A1 (en) | 2003-04-03 |
DK1429802T3 (da) | 2013-02-18 |
WO2003026687A1 (en) | 2003-04-03 |
CA2461708C (en) | 2012-08-07 |
CA2461708A1 (en) | 2003-04-03 |
US8007777B2 (en) | 2011-08-30 |
EP1429802A4 (en) | 2007-11-07 |
US20050152966A1 (en) | 2005-07-14 |
KR100979877B1 (ko) | 2010-09-02 |
US20030096002A1 (en) | 2003-05-22 |
HK1066969A1 (en) | 2005-03-18 |
CA2778208C (en) | 2015-11-10 |
RU2004110617A (ru) | 2005-03-10 |
CN1596124A (zh) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100478026C (zh) | 用于生物学组分的传递系统 | |
US8540980B2 (en) | Delivery system for biological component | |
AU2002330187A1 (en) | Delivery system for biological component | |
US20150050245A1 (en) | Methods and delivery system for beneficial additive and subtractive biological agents to promote balanced mammalian gastrointestinal flora | |
KR101147666B1 (ko) | 위 정체 제제 | |
AU2015284425B2 (en) | Bi-layer dual release probiotic tablets | |
EP1928426B1 (de) | Verfahren zur stabilisierung von pharmazeutischen darreichungsformen enthaltend mikroorganismen | |
CA2142142A1 (en) | Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract | |
EP4019028A1 (en) | Bacterial compositions | |
EP2234607B1 (en) | A slow-release formulation based on an association of glycogen and alginate | |
CN101607086B (zh) | 一种复方铋剂组合物及其制备方法 | |
EP1383375B1 (en) | A release pharmaceutical construct for gastric retention | |
JP5073174B2 (ja) | 生菌剤や消化酵素剤およびその両方を含有する錠剤の製造方法 | |
AU2002256333A1 (en) | A release pharmaceutical construct for gastric retention | |
JPH05255067A (ja) | 浮遊性製剤およびその製造方法 | |
JP2002205938A (ja) | 徐放性組成物および徐放性制御方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TNT CAMPBELL CO. Free format text: FORMER OWNER: NUTRACEUTIX INC. Effective date: 20111122 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111122 Address after: Washington, USA Patentee after: TNT Gan Bao Co. Address before: Washington, USA Patentee before: NUTRACEUTIX, Inc. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170921 Address after: Washington State Patentee after: TNTGAMBLE, Inc. Address before: Washington, USA Patentee before: TNT Gan Bao Co. |
|
CX01 | Expiry of patent term |
Granted publication date: 20090415 |
|
CX01 | Expiry of patent term |